To The Moon
Home
News
TigerAI
Log In
Sign Up
Squid
+Follow
Posts · 41
Posts · 41
Following · 0
Following · 0
Followers · 0
Followers · 0
Squid
Squid
·
2022-04-01
[Smile]
U.S. Probes Meeting Between Activision CEO And Option Buyer
Authorities investigating timely trading in Activision Blizzard Inc. securities are looking into at
U.S. Probes Meeting Between Activision CEO And Option Buyer
看
3.30K
回复
Comment
点赞
4
编组 21备份 2
Share
Report
Squid
Squid
·
2022-03-31
[What]
Adagio Stock Spikes on New Data, but Its Omicron Problems Remain
Roughly three months after an embarrassing reversal on the efficacy of its Covid-19 antibody against
Adagio Stock Spikes on New Data, but Its Omicron Problems Remain
看
5.53K
回复
Comment
点赞
6
编组 21备份 2
Share
Report
Squid
Squid
·
2022-03-30
[Speechless]
FDA Authorizes Fourth Pfizer and Moderna Covid Vaccine Doses for People Age 50 and Older
The Food and Drug Administration has authorized fourth Pfizer and Moderna Covid vaccine dose for eve
FDA Authorizes Fourth Pfizer and Moderna Covid Vaccine Doses for People Age 50 and Older
看
3.81K
回复
Comment
点赞
2
编组 21备份 2
Share
Report
Squid
Squid
·
2022-03-28
[Smile]
Is It Too Late to Buy Tesla Stock?
In two years, the stock price has increased by more than 10 times.
Is It Too Late to Buy Tesla Stock?
看
4.81K
回复
Comment
点赞
7
编组 21备份 2
Share
Report
Squid
Squid
·
2022-03-25
☹️
Vaccine Stocks Fell in Morning Trading ,with Moderna and Novavax Sliding Over 5%
Vaccine stocks fell in morning trading, with Moderna and Novavax sliding over 5%.
Vaccine Stocks Fell in Morning Trading ,with Moderna and Novavax Sliding Over 5%
看
4.07K
回复
Comment
点赞
4
编组 21备份 2
Share
Report
Squid
Squid
·
2022-03-24
👍
Sorry, this post has been deleted
看
3.44K
回复
Comment
点赞
1
编组 21备份 2
Share
Report
Squid
Squid
·
2022-03-23
Unpredictable
Hot Chinese ADRs Slid in Morning Trading, with Bilibili Tumbling Over 6% and JD.com Falling Over 3%
Hot Chinese ADRs Slid in Morning Trading, with Bilibili Tumbling Over 6% and JD.com Falling Over 3%
看
3.72K
回复
Comment
点赞
2
编组 21备份 2
Share
Report
Squid
Squid
·
2022-03-22
[Miser]
Want $1 Million In Retirement? Invest $100,000 in Any of These 3 Stocks and Wait A Decade
Younger investors saving for retirement have one significant advantage -- the ability to take on mor
Want $1 Million In Retirement? Invest $100,000 in Any of These 3 Stocks and Wait A Decade
看
3.73K
回复
Comment
点赞
2
编组 21备份 2
Share
Report
Squid
Squid
·
2022-03-21
[Smile]
Sorry, this post has been deleted
看
4.32K
回复
Comment
点赞
6
编组 21备份 2
Share
Report
Squid
Squid
·
2022-03-17
[Tongue]
Stocks Fall after Back-To-Back Rallies as Investors Digest Ukraine, Fed Developments
U.S. stocks stumbled Thursday morning following apivotal day on Wall Streetmarked by the Federal Res
Stocks Fall after Back-To-Back Rallies as Investors Digest Ukraine, Fed Developments
看
3.08K
回复
Comment
点赞
4
编组 21备份 2
Share
Report
Load more
Most Discussed
{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"4101354765322210","uuid":"4101354765322210","gmtCreate":1638275216942,"gmtModify":1638275216942,"name":"Squid","pinyin":"squid","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":4,"tweetSize":41,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.15","exceedPercentage":"80.21%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.01.09","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.08.02","exceedPercentage":"80.07%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.02","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.25","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":9011079340,"gmtCreate":1648794775924,"gmtModify":1676534399765,"author":{"id":"4101354765322210","authorId":"4101354765322210","name":"Squid","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4101354765322210","authorIdStr":"4101354765322210"},"themes":[],"htmlText":"[Smile] ","listText":"[Smile] ","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9011079340","repostId":"2224978395","repostType":4,"repost":{"id":"2224978395","kind":"highlight","pubTimestamp":1648782565,"share":"https://ttm.financial/m/news/2224978395?lang=en_US&edition=fundamental","pubTime":"2022-04-01 11:09","market":"us","language":"en","title":"U.S. Probes Meeting Between Activision CEO And Option Buyer","url":"https://stock-news.laohu8.com/highlight/detail?id=2224978395","media":"The Wall Street Journal","summary":"Authorities investigating timely trading in Activision Blizzard Inc. securities are looking into at","content":"<html><head></head><body><p>Authorities investigating timely trading in <a href=\"https://laohu8.com/S/ATVI\">Activision Blizzard Inc. </a> securities are looking into at least one meeting between the videogame firm’s chief executive and one of three traders days before they placed a large bet on Activision shares, according to people familiar with the matter.</p><p>Activision CEO Bobby Kotick met with Alexander von Furstenberg in the week before Mr. von Furstenberg and media moguls Barry Diller and David Geffen bought options to purchase Activision shares at $40 each on Jan. 14. The options trade, which has generated an unrealized profit of about $59 million, was arranged days before Activision agreed to be acquired for $95 a share by <a href=\"https://laohu8.com/S/MSFT\">Microsoft Corp.</a>, The Wall Street Journal has reported.</p><p>The Justice Department is investigating whether the options trade violated insider-trading laws, the people familiar with the matter said. The Securities and Exchange Commission is separately conducting a civil insider-trading investigation, the people said.</p><p>Mr. Diller previously told the Journal in an interview that none of the men had material nonpublic information about the Microsoft-Activision deal. He confirmed they had been contacted by regulators.</p><p>“We had zero knowledge of that transaction and it belies credulity to think that if we did we would have proceeded,” Mr. Diller wrote Thursday in an email to the Journal. “It’s equally unlikely to believe Mr. Kotick, a sophisticated professional, in a social breakfast with Mr. von Furstenberg and his wife would have told them of the pending transaction.”</p><p>Mr. von Furstenberg disclosed his breakfast meeting with Mr. Kotick to law-enforcement authorities who interviewed him about the trade, according to a person familiar with the matter. Messrs. von Furstenberg and Geffen haven’t responded to the Journal’s requests for comment.</p><p>Mr. Kotick’s status in the investigation couldn’t be learned. He hasn’t been interviewed by law-enforcement authorities, some of the people said. The Justice Department declined to comment. The SEC declined to comment.</p><p>“Mr. Kotick had a social brunch with his friends at a popular restaurant,” an Activision spokesman said. “He, of course, didn’t share any information with them regarding a possible transaction with Microsoft.”</p><p>The meeting between Messrs. von Furstenberg and Kotick adds to the growing regulatory pressure on Activision and Mr. Kotick personally. The SEC is separately investigating Mr. Kotick and other Activision executives over how they handled workplace misconduct allegations, the Journal has reported, citing documents and people familiar with the investigation. That probe, along with an investigation led by the California Department of Fair Employment and Housing, has escalated since the Microsoft deal was announced. Activision has said it is cooperating with the SEC probe and has called a recent move by the California state agency to subpoena police records “an extraordinary fishing expedition.”</p><p>Mr. Kotick and Activision have been under intense scrutiny from employees, investors and regulators since a July lawsuit from the California state agency that alleged a culture of sexual harassment and gender pay disparity. Soon after the Journal reported in November that Mr. Kotick knew of some sexual harassment claims and didn’t report them to Activision’s board of directors, Microsoft reached out about a possible deal, the Journal has reported. Mr. Kotick has said he has been transparent with his board of directors, and Activision has called the Journal’s reporting “misleading.”</p><p>On Wednesday, a federal judge approved an $18 million settlement between Activision and the Equal Employment Opportunity Commission, which has been investigating Activision since 2018.</p><p>Experts said regulatory investigations are unlikely to derail the deal with Microsoft unless there is a so-called material adverse change that would affect the value of the deal, which is expected to close sometime next year. Mr. Kotick isn’t expected to remain at Microsoft, people familiar with the matter said.</p><p>Microsoft is required to pay Activision a breakup fee of about $3 billion after April 18, 2023, if Microsoft walks away from the deal, securities filings show. If Activision abandons the deal, it must pay about $2.3 billion.</p><p>Mr. von Furstenberg arranged the options trade through JPMorgan Chase & Co. for himself and Messrs. Diller and Geffen, according to some of the people familiar with the matter. Mr. Geffen believed Activision was undervalued and would be acquired or taken private, and first contacted Mr. Diller with the idea for the trade, according to Mr. Diller.</p><p>“It’s a simple situation and a simple coincidence, which took place over 2 business days,” Mr. Diller wrote in the email. “All the information and records we are giving to the investigators will support that. I did not wait until I was 80 to participate in so obvious a fraud.”</p><p>Mr. von Furstenberg is Mr. Diller’s stepson, and Messrs. Diller and Geffen are longtime friends. Mr. Kotick is a longtime friend of Messrs. Diller and von Furstenberg, according to people familiar with their relationship.</p><p>Activision shares were around $63 at the time of the trade, meaning the options already were profitable to exercise, or “in the money.” Options holders stood to reap more if Activision’s stock price rose.</p><p>Mr. von Furstenberg is the founder and chief investment officer of Ranger Global Advisors LLC, a company that manages his family’s fortune, according to his LinkedIn profile and Ranger’s website. The firm manages more than $1 billion, the website says. An officer of Ranger Global Advisors declined to comment.</p><p>Call options give a trader the right to buy shares at a specific price by a certain date. The three men have yet to exercise the options, which don’t expire until early next year, the people said.</p><p>Traders using options are often looking to profit from a swing in share prices. Because options typically cost less than shares, they can amplify gains when traders bet right, particularly when they purchased options that were “out of the money”—the term for bets that aren’t profitable at the time the options are purchased. Options that are “in the money” at purchase tend to be more expensive and less risky because they can be immediately profitable to exercise.</p><p>The traders appear to have spent around $108 million to acquire the right to buy 4.12 million Activision shares, the people said. Those options if exercised today would be worth around $167 million, based on recent trading prices.</p><p>The value of the options would rise further if the deal closes at the stated per-share price of $95, which Microsoft has said is expected after midyear, compared with Activision stock’s Wednesday closing price of $80.36. If the men hold the options through a closing at that price, their profit stands to surpass $100 million, the people said.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. Probes Meeting Between Activision CEO And Option Buyer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. Probes Meeting Between Activision CEO And Option Buyer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-01 11:09 GMT+8 <a href=https://www.wsj.com/articles/u-s-probes-meeting-between-activision-ceo-and-option-buyer-11648754313?mod=newsviewer_click_seemore><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Authorities investigating timely trading in Activision Blizzard Inc. securities are looking into at least one meeting between the videogame firm’s chief executive and one of three traders days before...</p>\n\n<a href=\"https://www.wsj.com/articles/u-s-probes-meeting-between-activision-ceo-and-option-buyer-11648754313?mod=newsviewer_click_seemore\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4561":"索罗斯持仓","ATVI":"动视暴雪","BK4524":"宅经济概念","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","MSFT":"微软","BK4577":"网络游戏"},"source_url":"https://www.wsj.com/articles/u-s-probes-meeting-between-activision-ceo-and-option-buyer-11648754313?mod=newsviewer_click_seemore","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2224978395","content_text":"Authorities investigating timely trading in Activision Blizzard Inc. securities are looking into at least one meeting between the videogame firm’s chief executive and one of three traders days before they placed a large bet on Activision shares, according to people familiar with the matter.Activision CEO Bobby Kotick met with Alexander von Furstenberg in the week before Mr. von Furstenberg and media moguls Barry Diller and David Geffen bought options to purchase Activision shares at $40 each on Jan. 14. The options trade, which has generated an unrealized profit of about $59 million, was arranged days before Activision agreed to be acquired for $95 a share by Microsoft Corp., The Wall Street Journal has reported.The Justice Department is investigating whether the options trade violated insider-trading laws, the people familiar with the matter said. The Securities and Exchange Commission is separately conducting a civil insider-trading investigation, the people said.Mr. Diller previously told the Journal in an interview that none of the men had material nonpublic information about the Microsoft-Activision deal. He confirmed they had been contacted by regulators.“We had zero knowledge of that transaction and it belies credulity to think that if we did we would have proceeded,” Mr. Diller wrote Thursday in an email to the Journal. “It’s equally unlikely to believe Mr. Kotick, a sophisticated professional, in a social breakfast with Mr. von Furstenberg and his wife would have told them of the pending transaction.”Mr. von Furstenberg disclosed his breakfast meeting with Mr. Kotick to law-enforcement authorities who interviewed him about the trade, according to a person familiar with the matter. Messrs. von Furstenberg and Geffen haven’t responded to the Journal’s requests for comment.Mr. Kotick’s status in the investigation couldn’t be learned. He hasn’t been interviewed by law-enforcement authorities, some of the people said. The Justice Department declined to comment. The SEC declined to comment.“Mr. Kotick had a social brunch with his friends at a popular restaurant,” an Activision spokesman said. “He, of course, didn’t share any information with them regarding a possible transaction with Microsoft.”The meeting between Messrs. von Furstenberg and Kotick adds to the growing regulatory pressure on Activision and Mr. Kotick personally. The SEC is separately investigating Mr. Kotick and other Activision executives over how they handled workplace misconduct allegations, the Journal has reported, citing documents and people familiar with the investigation. That probe, along with an investigation led by the California Department of Fair Employment and Housing, has escalated since the Microsoft deal was announced. Activision has said it is cooperating with the SEC probe and has called a recent move by the California state agency to subpoena police records “an extraordinary fishing expedition.”Mr. Kotick and Activision have been under intense scrutiny from employees, investors and regulators since a July lawsuit from the California state agency that alleged a culture of sexual harassment and gender pay disparity. Soon after the Journal reported in November that Mr. Kotick knew of some sexual harassment claims and didn’t report them to Activision’s board of directors, Microsoft reached out about a possible deal, the Journal has reported. Mr. Kotick has said he has been transparent with his board of directors, and Activision has called the Journal’s reporting “misleading.”On Wednesday, a federal judge approved an $18 million settlement between Activision and the Equal Employment Opportunity Commission, which has been investigating Activision since 2018.Experts said regulatory investigations are unlikely to derail the deal with Microsoft unless there is a so-called material adverse change that would affect the value of the deal, which is expected to close sometime next year. Mr. Kotick isn’t expected to remain at Microsoft, people familiar with the matter said.Microsoft is required to pay Activision a breakup fee of about $3 billion after April 18, 2023, if Microsoft walks away from the deal, securities filings show. If Activision abandons the deal, it must pay about $2.3 billion.Mr. von Furstenberg arranged the options trade through JPMorgan Chase & Co. for himself and Messrs. Diller and Geffen, according to some of the people familiar with the matter. Mr. Geffen believed Activision was undervalued and would be acquired or taken private, and first contacted Mr. Diller with the idea for the trade, according to Mr. Diller.“It’s a simple situation and a simple coincidence, which took place over 2 business days,” Mr. Diller wrote in the email. “All the information and records we are giving to the investigators will support that. I did not wait until I was 80 to participate in so obvious a fraud.”Mr. von Furstenberg is Mr. Diller’s stepson, and Messrs. Diller and Geffen are longtime friends. Mr. Kotick is a longtime friend of Messrs. Diller and von Furstenberg, according to people familiar with their relationship.Activision shares were around $63 at the time of the trade, meaning the options already were profitable to exercise, or “in the money.” Options holders stood to reap more if Activision’s stock price rose.Mr. von Furstenberg is the founder and chief investment officer of Ranger Global Advisors LLC, a company that manages his family’s fortune, according to his LinkedIn profile and Ranger’s website. The firm manages more than $1 billion, the website says. An officer of Ranger Global Advisors declined to comment.Call options give a trader the right to buy shares at a specific price by a certain date. The three men have yet to exercise the options, which don’t expire until early next year, the people said.Traders using options are often looking to profit from a swing in share prices. Because options typically cost less than shares, they can amplify gains when traders bet right, particularly when they purchased options that were “out of the money”—the term for bets that aren’t profitable at the time the options are purchased. Options that are “in the money” at purchase tend to be more expensive and less risky because they can be immediately profitable to exercise.The traders appear to have spent around $108 million to acquire the right to buy 4.12 million Activision shares, the people said. Those options if exercised today would be worth around $167 million, based on recent trading prices.The value of the options would rise further if the deal closes at the stated per-share price of $95, which Microsoft has said is expected after midyear, compared with Activision stock’s Wednesday closing price of $80.36. If the men hold the options through a closing at that price, their profit stands to surpass $100 million, the people said.","news_type":1,"symbols_score_info":{"MSFT":0.9,"ATVI":1}},"isVote":1,"tweetType":1,"viewCount":3295,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9013052948,"gmtCreate":1648657003347,"gmtModify":1676534373203,"author":{"id":"4101354765322210","authorId":"4101354765322210","name":"Squid","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4101354765322210","authorIdStr":"4101354765322210"},"themes":[],"htmlText":"[What] ","listText":"[What] ","text":"[What]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9013052948","repostId":"1154741990","repostType":4,"repost":{"id":"1154741990","kind":"news","pubTimestamp":1648650278,"share":"https://ttm.financial/m/news/1154741990?lang=en_US&edition=fundamental","pubTime":"2022-03-30 22:24","market":"us","language":"en","title":"Adagio Stock Spikes on New Data, but Its Omicron Problems Remain","url":"https://stock-news.laohu8.com/highlight/detail?id=1154741990","media":"Barrons","summary":"Roughly three months after an embarrassing reversal on the efficacy of its Covid-19 antibody against","content":"<html><head></head><body><p>Roughly three months after an embarrassing reversal on the efficacy of its Covid-19 antibody against the Omicron variant, the small-cap biotech Adagio Therapeutics is back with new data, and says it will proceed with asking the Food and Drug Administration to authorize its drug.</p><p>Adagio says that the drug, ADG20, reduced the risk of Covid-19 by 71% when given as a pre-exposure prophylaxis, and 75% when given as a post-exposure prophylaxis. As a treatment to patients with mild to moderate Covid-19, it reduced the risk of hospitalization and death by 77%.</p><p>The drug’s Omicron problems, however, don’t seem to have been resolved. Nearly all of the data was collected before the Omicron variant, and the data collected amid Omicron appears to show a weaker benefit than the other results. The company’s struggles highlight the weaknesses of monoclonal antibody therapies overall as a tool against Covid-19—something the Omicron variant revealed.</p><p>The company acknowledged in its Wednesday statement that the trials were “primarily conducted” before the emergence of Omicron as the dominant variant in the U.S.</p><p>Adagio said it will seek an emergency use authorization for ADG20, also known as adintrevimab, for prevention and treatment of Covid-19 in the second quarter.</p><p>Shares of Adagio (ticker: ADGI) rose as much as 72.9% in premarket trading Wednesday to $6.62, from Tuesday’s closing price of $3.85. That spike moderated slightly as the morning progressed, and the stock was up about 42%, to $5.47, at 10:25 a.m.</p><p><img src=\"https://static.tigerbbs.com/fc4854729b746a60fe555e8e89ed4339\" tg-width=\"840\" tg-height=\"617\" width=\"100%\" height=\"auto\"/></p><p>Shares closed as high as $47.04 in November, when the company issued a release in which it claimed that ADG20 would protect against the Omicron variant, based on its understanding of how ADG20 binds to the virus that causes Covid-19. Laboratory data released in December, however, didn’t support those claims.</p><p>Shares plunged by 78.8% in a single day in mid-December after the company announced the results of its lab tests. The reversal was followed months later by the resignation of the company’s CEO. Adagio is currently being led on an interim basis by its former chief operating officer, David Hering.</p><p>Hering, said in Wednesday’s statement that he was “optimistic about the road ahead.” But it’s not at all clear that Adagio has gotten over its Omicron problem.</p><p>Data from one portion of the trial conducted after the emergence of Omicron is not as strong as the pre-Omicron data. An exploratory analysis after the emergence of Omicron followed 402 participants who received ADG20 as a pre-exposure prophylaxis, and found that the relative risk reduction in the group who received the treatment compared to the placebo group was 47% after 77 days. Before Omicron, the relative risk reduction as a pre-exposure prophylaxis was 71% after three months.</p><p>“We are encouraged by the data and look forward to submitting an EUA and discussing these results with the FDA and other regulatory authorities,” said Adagio’s chief development officer, Ellie Hershberger, in a statement.</p><p>The company’s struggles with Omicron offer yet another example of the shortcomings of monoclonal antibodies as a tool against a fast-changing virus like SARS-CoV-2. Last week, the FDA limited the use of sotrovimab, a Covid-19 monoclonal antibody therapy from GlaxoSmithKline (GSK) and Vir Biotechnology (VIR), after studies showed that it was likely not effective against the Omicron subvariant BA.2.</p><p>That came just months after the FDA revoked authorizations of other available monoclonal antibody therapies, which hadn’t worked against the original Omicron variant.</p><p>Adagio did not mention ADG20’s efficacy against BA.2 in its news release. Last week, the journal Nature Medicine published a paper that found that ADG20, along with many other antibody therapies, was “inactive” against BA.2.</p><p>Also on Wednesday, Adagio announced full-year financial results for 2021, saying it had $591.4 million in cash and cash equivalents as of the end of 2021, enough to fund its operations through the second half of 2024.</p></body></html>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adagio Stock Spikes on New Data, but Its Omicron Problems Remain</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdagio Stock Spikes on New Data, but Its Omicron Problems Remain\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-30 22:24 GMT+8 <a href=https://www.barrons.com/articles/adagio-stock-covid-antibody-drug-data-51648647002?mod=hp_LATEST><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Roughly three months after an embarrassing reversal on the efficacy of its Covid-19 antibody against the Omicron variant, the small-cap biotech Adagio Therapeutics is back with new data, and says it ...</p>\n\n<a href=\"https://www.barrons.com/articles/adagio-stock-covid-antibody-drug-data-51648647002?mod=hp_LATEST\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.barrons.com/articles/adagio-stock-covid-antibody-drug-data-51648647002?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154741990","content_text":"Roughly three months after an embarrassing reversal on the efficacy of its Covid-19 antibody against the Omicron variant, the small-cap biotech Adagio Therapeutics is back with new data, and says it will proceed with asking the Food and Drug Administration to authorize its drug.Adagio says that the drug, ADG20, reduced the risk of Covid-19 by 71% when given as a pre-exposure prophylaxis, and 75% when given as a post-exposure prophylaxis. As a treatment to patients with mild to moderate Covid-19, it reduced the risk of hospitalization and death by 77%.The drug’s Omicron problems, however, don’t seem to have been resolved. Nearly all of the data was collected before the Omicron variant, and the data collected amid Omicron appears to show a weaker benefit than the other results. The company’s struggles highlight the weaknesses of monoclonal antibody therapies overall as a tool against Covid-19—something the Omicron variant revealed.The company acknowledged in its Wednesday statement that the trials were “primarily conducted” before the emergence of Omicron as the dominant variant in the U.S.Adagio said it will seek an emergency use authorization for ADG20, also known as adintrevimab, for prevention and treatment of Covid-19 in the second quarter.Shares of Adagio (ticker: ADGI) rose as much as 72.9% in premarket trading Wednesday to $6.62, from Tuesday’s closing price of $3.85. That spike moderated slightly as the morning progressed, and the stock was up about 42%, to $5.47, at 10:25 a.m.Shares closed as high as $47.04 in November, when the company issued a release in which it claimed that ADG20 would protect against the Omicron variant, based on its understanding of how ADG20 binds to the virus that causes Covid-19. Laboratory data released in December, however, didn’t support those claims.Shares plunged by 78.8% in a single day in mid-December after the company announced the results of its lab tests. The reversal was followed months later by the resignation of the company’s CEO. Adagio is currently being led on an interim basis by its former chief operating officer, David Hering.Hering, said in Wednesday’s statement that he was “optimistic about the road ahead.” But it’s not at all clear that Adagio has gotten over its Omicron problem.Data from one portion of the trial conducted after the emergence of Omicron is not as strong as the pre-Omicron data. An exploratory analysis after the emergence of Omicron followed 402 participants who received ADG20 as a pre-exposure prophylaxis, and found that the relative risk reduction in the group who received the treatment compared to the placebo group was 47% after 77 days. Before Omicron, the relative risk reduction as a pre-exposure prophylaxis was 71% after three months.“We are encouraged by the data and look forward to submitting an EUA and discussing these results with the FDA and other regulatory authorities,” said Adagio’s chief development officer, Ellie Hershberger, in a statement.The company’s struggles with Omicron offer yet another example of the shortcomings of monoclonal antibodies as a tool against a fast-changing virus like SARS-CoV-2. Last week, the FDA limited the use of sotrovimab, a Covid-19 monoclonal antibody therapy from GlaxoSmithKline (GSK) and Vir Biotechnology (VIR), after studies showed that it was likely not effective against the Omicron subvariant BA.2.That came just months after the FDA revoked authorizations of other available monoclonal antibody therapies, which hadn’t worked against the original Omicron variant.Adagio did not mention ADG20’s efficacy against BA.2 in its news release. Last week, the journal Nature Medicine published a paper that found that ADG20, along with many other antibody therapies, was “inactive” against BA.2.Also on Wednesday, Adagio announced full-year financial results for 2021, saying it had $591.4 million in cash and cash equivalents as of the end of 2021, enough to fund its operations through the second half of 2024.","news_type":1,"symbols_score_info":{"ADGI":0.9}},"isVote":1,"tweetType":1,"viewCount":5528,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9019854643,"gmtCreate":1648592253913,"gmtModify":1676534357231,"author":{"id":"4101354765322210","authorId":"4101354765322210","name":"Squid","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4101354765322210","authorIdStr":"4101354765322210"},"themes":[],"htmlText":"[Speechless] ","listText":"[Speechless] ","text":"[Speechless]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9019854643","repostId":"1169105288","repostType":4,"repost":{"id":"1169105288","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1648565236,"share":"https://ttm.financial/m/news/1169105288?lang=en_US&edition=fundamental","pubTime":"2022-03-29 22:47","market":"us","language":"en","title":"FDA Authorizes Fourth Pfizer and Moderna Covid Vaccine Doses for People Age 50 and Older","url":"https://stock-news.laohu8.com/highlight/detail?id=1169105288","media":"Tiger Newspress","summary":"The Food and Drug Administration has authorized fourth Pfizer and Moderna Covid vaccine dose for eve","content":"<html><head></head><body><p>The Food and Drug Administration has authorized fourth Pfizer and Moderna Covid vaccine dose for everyone age 50 and older, amid uncertainty over whether an even more contagious version omicron will cause another wave of infection in the U.S. as it has in Europe and China.</p><p>The FDA also authorized a second Pfizer booster shot for people age 12 and older who have compromised immune systems, and a second Moderna booster for adults ages 18 and older with compromised immune systems. The new boosters are administered at least fourth months after the last shot.</p><p>The FDA made the decision without a meeting of its vaccine advisory committee, a rare move the agency has made more frequently over the course of the pandemic to expand uses of Covid vaccines. The drug regulator’s authorization comes just two weeks after Pfizer and Moderna asked the FDA to permit a second booster shot based on data from Israel. The Centers for Disease Control and Prevention is expected to quickly sign off on the decision.</p><p>The FDA’s decision effectively bypasses its advisory committee on vaccines, which is scheduled to meet on April 6 to discuss the future of booster shots in the U.S. The vaccine experts are expected to hold a broad discussion about boosters and will not vote on a specific recommendation.</p><p>Pfizer shares added nearly 1% while Moderna stock rose more than3% in morning trading.</p><p><img src=\"https://static.tigerbbs.com/e97d79e4e9defe5fd766f4b1fe90ffc7\" tg-width=\"841\" tg-height=\"618\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/3cbfa17839071433be152b0c184f40c6\" tg-width=\"843\" tg-height=\"621\" width=\"100%\" height=\"auto\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Authorizes Fourth Pfizer and Moderna Covid Vaccine Doses for People Age 50 and Older</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Authorizes Fourth Pfizer and Moderna Covid Vaccine Doses for People Age 50 and Older\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-03-29 22:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>The Food and Drug Administration has authorized fourth Pfizer and Moderna Covid vaccine dose for everyone age 50 and older, amid uncertainty over whether an even more contagious version omicron will cause another wave of infection in the U.S. as it has in Europe and China.</p><p>The FDA also authorized a second Pfizer booster shot for people age 12 and older who have compromised immune systems, and a second Moderna booster for adults ages 18 and older with compromised immune systems. The new boosters are administered at least fourth months after the last shot.</p><p>The FDA made the decision without a meeting of its vaccine advisory committee, a rare move the agency has made more frequently over the course of the pandemic to expand uses of Covid vaccines. The drug regulator’s authorization comes just two weeks after Pfizer and Moderna asked the FDA to permit a second booster shot based on data from Israel. The Centers for Disease Control and Prevention is expected to quickly sign off on the decision.</p><p>The FDA’s decision effectively bypasses its advisory committee on vaccines, which is scheduled to meet on April 6 to discuss the future of booster shots in the U.S. The vaccine experts are expected to hold a broad discussion about boosters and will not vote on a specific recommendation.</p><p>Pfizer shares added nearly 1% while Moderna stock rose more than3% in morning trading.</p><p><img src=\"https://static.tigerbbs.com/e97d79e4e9defe5fd766f4b1fe90ffc7\" tg-width=\"841\" tg-height=\"618\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/3cbfa17839071433be152b0c184f40c6\" tg-width=\"843\" tg-height=\"621\" width=\"100%\" height=\"auto\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169105288","content_text":"The Food and Drug Administration has authorized fourth Pfizer and Moderna Covid vaccine dose for everyone age 50 and older, amid uncertainty over whether an even more contagious version omicron will cause another wave of infection in the U.S. as it has in Europe and China.The FDA also authorized a second Pfizer booster shot for people age 12 and older who have compromised immune systems, and a second Moderna booster for adults ages 18 and older with compromised immune systems. The new boosters are administered at least fourth months after the last shot.The FDA made the decision without a meeting of its vaccine advisory committee, a rare move the agency has made more frequently over the course of the pandemic to expand uses of Covid vaccines. The drug regulator’s authorization comes just two weeks after Pfizer and Moderna asked the FDA to permit a second booster shot based on data from Israel. The Centers for Disease Control and Prevention is expected to quickly sign off on the decision.The FDA’s decision effectively bypasses its advisory committee on vaccines, which is scheduled to meet on April 6 to discuss the future of booster shots in the U.S. The vaccine experts are expected to hold a broad discussion about boosters and will not vote on a specific recommendation.Pfizer shares added nearly 1% while Moderna stock rose more than3% in morning trading.","news_type":1,"symbols_score_info":{"MRNA":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":3807,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9010754511,"gmtCreate":1648477308918,"gmtModify":1676534342794,"author":{"id":"4101354765322210","authorId":"4101354765322210","name":"Squid","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4101354765322210","authorIdStr":"4101354765322210"},"themes":[],"htmlText":"[Smile] ","listText":"[Smile] ","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9010754511","repostId":"1101698141","repostType":4,"repost":{"id":"1101698141","kind":"news","pubTimestamp":1648473577,"share":"https://ttm.financial/m/news/1101698141?lang=en_US&edition=fundamental","pubTime":"2022-03-28 21:19","market":"us","language":"en","title":"Is It Too Late to Buy Tesla Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=1101698141","media":"Motley Fool","summary":"In two years, the stock price has increased by more than 10 times.","content":"<div>\n<p>KEY POINTSTesla's profit margin in the latest quarter was well ahead of traditional automakers.The company already has nearly 60,000 vehicles in its full self-driving beta program.The stock's ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/28/is-it-too-late-to-buy-tesla-stock/\">Source Link</a>\n\n</div>\n","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Too Late to Buy Tesla Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Too Late to Buy Tesla Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-28 21:19 GMT+8 <a href=https://www.fool.com/investing/2022/03/28/is-it-too-late-to-buy-tesla-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTSTesla's profit margin in the latest quarter was well ahead of traditional automakers.The company already has nearly 60,000 vehicles in its full self-driving beta program.The stock's ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/28/is-it-too-late-to-buy-tesla-stock/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.fool.com/investing/2022/03/28/is-it-too-late-to-buy-tesla-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101698141","content_text":"KEY POINTSTesla's profit margin in the latest quarter was well ahead of traditional automakers.The company already has nearly 60,000 vehicles in its full self-driving beta program.The stock's valuation doesn't make sense using traditional methods of measurement.If you had invested $100,000 in Tesla two years back, your investment would have grown by more than 10 times to $1.2 million today. Early Tesla investors are surely enjoying the stock's dramatic rise. But if you are among the ones who missed investing earlier, you must be wondering if it is already too late to invest in the electric vehicle (EV) pioneer.Let's discuss if it still makes sense to buy the stock.Tesla continues to growFounded in 2003, Tesla made its first annual profit, $721 million, in 2020. In 2021, the company's profit surged 665% to $5.5 billion. At the same time, its revenue grew 71% for the year. The strong growth was supported by an 87% increase in vehicle deliveries in 2021.A Tesla Model Y. Image source: Tesla.Most investors and analysts agree that Tesla is very likely to continue growing its vehicle deliveries. To that end, the company is opening new factories; it started deliveries from its German factory on Tuesday and is expected to open its Texas factory soon. In short, Tesla is well on its way to becoming one of the largest automakers in the world.And the company has managed to distinguish itself from traditional automakers by generating high margins.TSLA profit margin (quarterly). Data by YCharts.Ford's high margin in the chart above is attributable to a gain relating to its Rivian investment. It reported an adjusted EBIT (earnings before interest and tax) margin of 5.4% for the fourth quarter. So Tesla's profit margin in the latest quarter well exceeded that of traditional automakers.Those high margins can be attributed to several factors. The first one is high-margin services, including full self-driving (FSD) features and over-the-air software updates, which command higher profits than traditional vehicle sales. Other factors include high vertical integration, an absence of a dealer network, and low marketing expenses.Innovation is Tesla's key differentiatorDespite the high growth, at a $1 trillion market capitalization, value-focused investors are understandably wary of Tesla. But the stock has defied traditional valuation metrics so far. The big question is: Can it continue to do so?While no one can answer that question conclusively, I'm inclined toward a yes. Apart from high margins and scale, some other factors could support Tesla's valuation in the future. The top one is the automaker's FSD feature.Tesla already has nearly 60,000 vehicles in its FSD beta program. The Insurance Institute for Highway Safety has awarded the vision-only FSD version in certain Tesla models a score of \"superior\" in collision avoidance and has given it a Top Safety Pick+, the highest possible rating.The company could have significant potential to expand its margins if its FSD feature shapes up as the company is hoping. Though there are other companies working on autonomous driving -- such as Alphabet with its Waymo and General Motors with its Cruise -- Tesla could have an edge. With the large number of vehicles in use, it could have vastly more data to train its program than its competitors have. And FSD features developed in-house will again tap into the benefits of vertical integration. It could even offer the feature for a fee to other automakers. But this is just speculation and may not turn out as expected.Though it could be difficult to imagine what Tesla will do next, its growth hinges on innovation. And the company seems to have no dearth of it so far.Should you buy Tesla stock now?Tesla's higher margins give some credibility to the reasoning that it should be valued as a technology stock.TSLA market cap. Data by YCharts.Tesla's high earnings growth makes its forward price/earnings-to-growth (PEG) ratio attractive, despite its high price-to-earnings (P/E) ratio.TSLA PE ratio (forward 1 year). Data by YCharts.A PEG ratio compares a stock's P/E to the expected growth in its earnings. All other things being equal, the stock of a company growing its earnings at a higher rate is expected to trade at a higher P/E ratio.Tesla generated $5.5 billion in net income in 2021, selling nearly 1 million EVs. As the company's sales rise, its profits should increase proportionally, if the company maintains its margins. When that happens, Tesla stock's current valuation will start to make sense in retrospect. That's because the stock price will have likely risen more, making valuation incomprehensible again at that point in future!In short, while Tesla stock might not generate the 10-bagger returns it did in the past two years, it looks well positioned to generate market-beating returns in the years to come. So it's likely not too late to add this top stock to your portfolio.","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":4809,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9010906218,"gmtCreate":1648220316050,"gmtModify":1676534318871,"author":{"id":"4101354765322210","authorId":"4101354765322210","name":"Squid","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4101354765322210","authorIdStr":"4101354765322210"},"themes":[],"htmlText":"☹️","listText":"☹️","text":"☹️","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9010906218","repostId":"1185342631","repostType":4,"repost":{"id":"1185342631","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1648216987,"share":"https://ttm.financial/m/news/1185342631?lang=en_US&edition=fundamental","pubTime":"2022-03-25 22:03","market":"us","language":"en","title":"Vaccine Stocks Fell in Morning Trading ,with Moderna and Novavax Sliding Over 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1185342631","media":"Tiger Newspress","summary":"Vaccine stocks fell in morning trading, with Moderna and Novavax sliding over 5%.","content":"<html><head></head><body><p>Vaccine stocks fell in morning trading, with Moderna and Novavax sliding over 5%.<img src=\"https://static.tigerbbs.com/d0103a8781547bf097460898836002dd\" tg-width=\"317\" tg-height=\"242\" width=\"100%\" height=\"auto\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine Stocks Fell in Morning Trading ,with Moderna and Novavax Sliding Over 5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine Stocks Fell in Morning Trading ,with Moderna and Novavax Sliding Over 5%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-03-25 22:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Vaccine stocks fell in morning trading, with Moderna and Novavax sliding over 5%.<img src=\"https://static.tigerbbs.com/d0103a8781547bf097460898836002dd\" tg-width=\"317\" tg-height=\"242\" width=\"100%\" height=\"auto\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","MRNA":"Moderna, Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1185342631","content_text":"Vaccine stocks fell in morning trading, with Moderna and Novavax sliding over 5%.","news_type":1,"symbols_score_info":{"NVAX":0.9,"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":4073,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9037593922,"gmtCreate":1648131891373,"gmtModify":1676534307793,"author":{"id":"4101354765322210","authorId":"4101354765322210","name":"Squid","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4101354765322210","authorIdStr":"4101354765322210"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9037593922","repostId":"1137376008","repostType":4,"isVote":1,"tweetType":1,"viewCount":3440,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9037195779,"gmtCreate":1648046285407,"gmtModify":1676534296749,"author":{"id":"4101354765322210","authorId":"4101354765322210","name":"Squid","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4101354765322210","authorIdStr":"4101354765322210"},"themes":[],"htmlText":"Unpredictable ","listText":"Unpredictable ","text":"Unpredictable","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9037195779","repostId":"1192802620","repostType":4,"repost":{"id":"1192802620","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1648043886,"share":"https://ttm.financial/m/news/1192802620?lang=en_US&edition=fundamental","pubTime":"2022-03-23 21:58","market":"us","language":"en","title":"Hot Chinese ADRs Slid in Morning Trading, with Bilibili Tumbling Over 6% and JD.com Falling Over 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1192802620","media":"Tiger Newspress","summary":"","content":"<html><head></head><body><p><img src=\"https://static.tigerbbs.com/db408ee2996a093a4d32f808dbec7957\" tg-width=\"319\" tg-height=\"205\" width=\"100%\" height=\"auto\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hot Chinese ADRs Slid in Morning Trading, with Bilibili Tumbling Over 6% and JD.com Falling Over 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHot Chinese ADRs Slid in Morning Trading, with Bilibili Tumbling Over 6% and JD.com Falling Over 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-03-23 21:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><img src=\"https://static.tigerbbs.com/db408ee2996a093a4d32f808dbec7957\" tg-width=\"319\" tg-height=\"205\" width=\"100%\" height=\"auto\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JD":"京东","BLBLF":"Bilibili Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192802620","news_type":1,"symbols_score_info":{"JD":0.9,"BLBLF":0.9}},"isVote":1,"tweetType":1,"viewCount":3719,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9034425673,"gmtCreate":1647951876088,"gmtModify":1676534283767,"author":{"id":"4101354765322210","authorId":"4101354765322210","name":"Squid","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4101354765322210","authorIdStr":"4101354765322210"},"themes":[],"htmlText":"[Miser] ","listText":"[Miser] ","text":"[Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9034425673","repostId":"1150453839","repostType":4,"repost":{"id":"1150453839","kind":"news","pubTimestamp":1647962880,"share":"https://ttm.financial/m/news/1150453839?lang=en_US&edition=fundamental","pubTime":"2022-03-22 23:28","market":"us","language":"en","title":"Want $1 Million In Retirement? Invest $100,000 in Any of These 3 Stocks and Wait A Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=1150453839","media":"Motley Fool","summary":"Younger investors saving for retirement have one significant advantage -- the ability to take on mor","content":"<div>\n<p>Younger investors saving for retirement have one significant advantage -- the ability to take on more risk. Because they have a longer investment time horizon, they can afford to take chances on great...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/21/1-million-retirement-invest-100000-3-stocks/\">Source Link</a>\n\n</div>\n","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Want $1 Million In Retirement? Invest $100,000 in Any of These 3 Stocks and Wait A Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWant $1 Million In Retirement? Invest $100,000 in Any of These 3 Stocks and Wait A Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-22 23:28 GMT+8 <a href=https://www.fool.com/investing/2022/03/21/1-million-retirement-invest-100000-3-stocks/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Younger investors saving for retirement have one significant advantage -- the ability to take on more risk. Because they have a longer investment time horizon, they can afford to take chances on great...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/21/1-million-retirement-invest-100000-3-stocks/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DOCN":"DigitalOcean Holdings, Inc.","ROKU":"Roku Inc"},"source_url":"https://www.fool.com/investing/2022/03/21/1-million-retirement-invest-100000-3-stocks/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150453839","content_text":"Younger investors saving for retirement have one significant advantage -- the ability to take on more risk. Because they have a longer investment time horizon, they can afford to take chances on great stocks offering a high potential for long-term returns than older investors who are looking to buy stocks that are safer but invariably offer lower potential returns.Fortunately, many promising tech stocks hold the potential to increase their value by tenfold over time. Investors hoping to turn $100,000 into $1 million over the next 10 years could see such potential returns in Block, DigitalOcean, and Roku.1. BlockBlock has placed itself at the center of fintech in many developed countries. Its business-oriented Square ecosystem and its Cash App continue to grow by expanding into new markets and broadening its scope of business within existing countries.Block just entered its eighth country early this year by bringing its ecosystem into Spain. Now, due to its presence in three EU countries, the company once known as Square has an easier path to serving the rest of the Eurozone.Moreover, it added cryptocurrency capabilities with its Bitcoin trading platform in both Square and Cash App. This likely helped it almost catch up to PayPal Holdings' Venmo in terms of popularity. Also, according to Research and Markets, the addressable market for fintech is expected to reach $31.5 trillion by 2026, a 27% compound annual growth rate (CAGR) that should bring opportunities for lots of companies in this sector, including Square.Block increased its 2021 revenue by 86% compared with 2020, 57% if excluding Bitcoin. This led to adjusted earnings of $898 million in the same period, 111% higher than year-ago levels. Analysts only expect 7% revenue growth in 2022 before it rebounds to 22% the next year.Still, the stock has lost more than half of its value since its peak last summer. With a price-to-sales (P/S) ratio of about 4, it has fallen from the double-digit sales multiples of early last year. This makes it more reasonably priced as Block seeks to meet the financial needs of more businesses and individuals.2. DigitalOceanAt first glance, companies such as Amazon and Microsoft dominate the cloud industry and cater their services to lots of big names. However, their product offerings are not really catered to the specific needs of small- and medium-sized enterprises (SMEs). DigitalOcean has built a high-growth enterprise by filling that gap. But while it offers simple, affordable pricing plans tailored to the needs of SMEs, its most vital advantage seems to lie in its community. Members of this community give and receive advice, helping these businesses resolve IT challenges that might otherwise hamper smaller enterprises.Also, DigitalOcean already claims about 600,000 customers in 185 countries. and the cloud market should also leave plenty of room for company growth. Grand View Research estimates the cloud infrastructure market will grow to $1.55 trillion by 2030, up from $484 billion today.DigitalOcean's 2021 revenue of $429 million makes up only a tiny fraction of that addressable market, though that was a 35% increase compared with 2020. Moreover, it cut its yearly loss to about $20 million, down from $44 million in 2020. Furthermore, revenue estimates for between $564 million and $568 million amount to 32% growth if the estimate holds, pointing to little if any slowdowns.Additionally, the stock has dropped 55% from its November high, taking its P/S ratio down to around 13. While this is higher than its larger competitors, a lower stock price and rapid revenue growth rate should take this stock much higher as the need for the cloud within SMEs continues to expand.3. RokuRoku has managed to capitalize on the transition of televised media to streaming. Through its aggregation of services and the offering of its Roku platform and channel, it provides an avenue by which companies can fund programming through advertising.Furthermore, Roku continues its expansion into Europe and Latin America, giving it leverage as companies like Alphabet attempt to compete. Additionally, the company has integrated its operating system into new televisions and offered its equipment at a low cost, easing the adoption of its platform.Roku claimed about 60 million users as of the end of 2021. Also, Research and Markets forecasts that the global digital advertising market will grow to $764 billion by 2025 and to $1.45 trillion by 2030 for a CAGR of 13.7%. Roku appears well-positioned to capture much of this increase as it currently only operates in roughly 20 countries and has plans for further expansion.So far, Roku has barely begun to scratch the surface of its potential. In 2021, it generated almost $2.8 billion in revenue, 55% more than in 2020. The revenue growth helped the company earn $242 million in net income, an improvement from the $18 million loss in 2020.Admittedly, the first-quarter outlook for 25% year-over-year revenue growth represents a slowdown. Still, the stock has fallen by about 75% from its high last July. Also, the P/S ratio now stands at six, down from 33 last February. These factors should more than price in the revenue growth slowdown into the stock, making Roku stock a buy now.","news_type":1,"symbols_score_info":{"SQ":0.9,"DOCN":0.9,"ROKU":0.9}},"isVote":1,"tweetType":1,"viewCount":3732,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9034878816,"gmtCreate":1647866673351,"gmtModify":1676534273347,"author":{"id":"4101354765322210","authorId":"4101354765322210","name":"Squid","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4101354765322210","authorIdStr":"4101354765322210"},"themes":[],"htmlText":"[Smile] ","listText":"[Smile] ","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9034878816","repostId":"1135376786","repostType":4,"isVote":1,"tweetType":1,"viewCount":4315,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9035344744,"gmtCreate":1647525073742,"gmtModify":1676534240298,"author":{"id":"4101354765322210","authorId":"4101354765322210","name":"Squid","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4101354765322210","authorIdStr":"4101354765322210"},"themes":[],"htmlText":"[Tongue] ","listText":"[Tongue] ","text":"[Tongue]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9035344744","repostId":"1157445332","repostType":4,"repost":{"id":"1157445332","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1647523849,"share":"https://ttm.financial/m/news/1157445332?lang=en_US&edition=fundamental","pubTime":"2022-03-17 21:30","market":"us","language":"en","title":"Stocks Fall after Back-To-Back Rallies as Investors Digest Ukraine, Fed Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=1157445332","media":"Tiger Newspress","summary":"U.S. stocks stumbled Thursday morning following apivotal day on Wall Streetmarked by the Federal Res","content":"<html><head></head><body><p>U.S. stocks stumbled Thursday morning following apivotal day on Wall Streetmarked by the Federal Reserve’s long-anticipated move to hike short-term interest rates for the first time in three years.</p><p>The S&P 500 was down 0.5% as of 9:30 a.m. ET to 4,336.06 and the Dow Jones Industrial Average shed about 160 points to 13,334.07. The Nasdaq Composite edged 0.7% lower to 13,348.17. Meanwhile, WTI Crude Oil futures gained 6.8% to rise above $100 per barrel.</p><p>At the end of its two-day policy-setting meeting, the central bank revealed Wednesday that it willlift the benchmark Federal Funds Rate by 0.25%, to a target range of 0.25% to 0.50%. The move was in line with what market participants had anticipated after Fed Chair Jerome Powell indicated in Congressional testimony earlier this month a 25 basis-point bump was distinctly possible.</p><p>“By raising interest rates, the Federal Reserve has begun the process of unwinding their pandemic-era stimulus measures in an effort to tame inflation,” Bankrate chief financial analyst Greg McBride said in a note. “This isn’t a one-and-done but the start of a series of rate hikes for the remainder of this year and well into next.”</p><p>The Fed also unveiled in its updated Summary of Economic Projections, or "dot plot," which reflects the individual economic projections of policymakers on the Federal Open Market Committee, that the median member anticipates up to six more rate hikes in 2022, which would bring rates 1.75% higher at the end of this year. Before Wednesday’s decision, the benchmark interest rate was deliberately held near zero since mid-2020 as part of the Fed’s easy-money policies used to keep financial conditions running smoothly during the pandemic.</p><p>“The Fed didn’t rock the boat much,” LPL Financial chief market strategist Ryan Detrick said. “Yes, they lowered economic expectations in 2022 while also increasing inflation, but much of that was already priced into things. Overall, they still see strong growth, which helps support the recovery.”</p><p>Although the key decision provided some clarity to investors who for months have awaited for the central bank to take steps forward on tightening monetary conditions, the Fed’s path forward remains muddied by geopolitical turmoil in Eastern Europe. War in Ukraine and penalizing sanctions against Russia for its invasion of the country have raised uncertainty in recent weeks over the conflict’s toll on the global economic picture.</p><p>The Fed acknowledged in a statement that came out of its meeting that implications for the U.S. economy are “highly uncertain” but likely to worsen already decades-high inflationary pressures.</p><p>“Playing catch up is the theme that Fed officials signaled to markets today as the narrative has shifted from normalizing monetary policy to laying the groundwork for a more restrictive policy and moving beyond neutral,” Allianz Investment Management senior market strategist Charlie Ripley said in commentary.</p><p>Elsewhere in markets, shares of Warren Buffett's Berkshire Hathaway closed at $500,000 for the first time on Wednesday. The price underscored Berkshire's status as a defensive stock at a time markets have been roiled by economic and geopolitical uncertainty.</p><p>Berkshire's Class A shares have advanced 10% in 2022, even as the S&P 500 is down about 12% year-to-date. Prior to a relief rally on Wednesday, the benchmark index on Tuesday (the 50th trading day of the year) locked in its 6th worst start to a year ever, data from LPL financial reflected. The silver lining? The previous five worst starts were followed by notable gains, with an average gain for the rest of the year of 36%, with the exception of only 2001.</p><p>“Although we aren’t expecting 36% gains the rest of this year, it does suggest that things might be quite bad now, but we’ve been here before and we’ve seen stocks come back way more than expected,” LPL’s Detrick said.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks Fall after Back-To-Back Rallies as Investors Digest Ukraine, Fed Developments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks Fall after Back-To-Back Rallies as Investors Digest Ukraine, Fed Developments\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-03-17 21:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>U.S. stocks stumbled Thursday morning following apivotal day on Wall Streetmarked by the Federal Reserve’s long-anticipated move to hike short-term interest rates for the first time in three years.</p><p>The S&P 500 was down 0.5% as of 9:30 a.m. ET to 4,336.06 and the Dow Jones Industrial Average shed about 160 points to 13,334.07. The Nasdaq Composite edged 0.7% lower to 13,348.17. Meanwhile, WTI Crude Oil futures gained 6.8% to rise above $100 per barrel.</p><p>At the end of its two-day policy-setting meeting, the central bank revealed Wednesday that it willlift the benchmark Federal Funds Rate by 0.25%, to a target range of 0.25% to 0.50%. The move was in line with what market participants had anticipated after Fed Chair Jerome Powell indicated in Congressional testimony earlier this month a 25 basis-point bump was distinctly possible.</p><p>“By raising interest rates, the Federal Reserve has begun the process of unwinding their pandemic-era stimulus measures in an effort to tame inflation,” Bankrate chief financial analyst Greg McBride said in a note. “This isn’t a one-and-done but the start of a series of rate hikes for the remainder of this year and well into next.”</p><p>The Fed also unveiled in its updated Summary of Economic Projections, or "dot plot," which reflects the individual economic projections of policymakers on the Federal Open Market Committee, that the median member anticipates up to six more rate hikes in 2022, which would bring rates 1.75% higher at the end of this year. Before Wednesday’s decision, the benchmark interest rate was deliberately held near zero since mid-2020 as part of the Fed’s easy-money policies used to keep financial conditions running smoothly during the pandemic.</p><p>“The Fed didn’t rock the boat much,” LPL Financial chief market strategist Ryan Detrick said. “Yes, they lowered economic expectations in 2022 while also increasing inflation, but much of that was already priced into things. Overall, they still see strong growth, which helps support the recovery.”</p><p>Although the key decision provided some clarity to investors who for months have awaited for the central bank to take steps forward on tightening monetary conditions, the Fed’s path forward remains muddied by geopolitical turmoil in Eastern Europe. War in Ukraine and penalizing sanctions against Russia for its invasion of the country have raised uncertainty in recent weeks over the conflict’s toll on the global economic picture.</p><p>The Fed acknowledged in a statement that came out of its meeting that implications for the U.S. economy are “highly uncertain” but likely to worsen already decades-high inflationary pressures.</p><p>“Playing catch up is the theme that Fed officials signaled to markets today as the narrative has shifted from normalizing monetary policy to laying the groundwork for a more restrictive policy and moving beyond neutral,” Allianz Investment Management senior market strategist Charlie Ripley said in commentary.</p><p>Elsewhere in markets, shares of Warren Buffett's Berkshire Hathaway closed at $500,000 for the first time on Wednesday. The price underscored Berkshire's status as a defensive stock at a time markets have been roiled by economic and geopolitical uncertainty.</p><p>Berkshire's Class A shares have advanced 10% in 2022, even as the S&P 500 is down about 12% year-to-date. Prior to a relief rally on Wednesday, the benchmark index on Tuesday (the 50th trading day of the year) locked in its 6th worst start to a year ever, data from LPL financial reflected. The silver lining? The previous five worst starts were followed by notable gains, with an average gain for the rest of the year of 36%, with the exception of only 2001.</p><p>“Although we aren’t expecting 36% gains the rest of this year, it does suggest that things might be quite bad now, but we’ve been here before and we’ve seen stocks come back way more than expected,” LPL’s Detrick said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157445332","content_text":"U.S. stocks stumbled Thursday morning following apivotal day on Wall Streetmarked by the Federal Reserve’s long-anticipated move to hike short-term interest rates for the first time in three years.The S&P 500 was down 0.5% as of 9:30 a.m. ET to 4,336.06 and the Dow Jones Industrial Average shed about 160 points to 13,334.07. The Nasdaq Composite edged 0.7% lower to 13,348.17. Meanwhile, WTI Crude Oil futures gained 6.8% to rise above $100 per barrel.At the end of its two-day policy-setting meeting, the central bank revealed Wednesday that it willlift the benchmark Federal Funds Rate by 0.25%, to a target range of 0.25% to 0.50%. The move was in line with what market participants had anticipated after Fed Chair Jerome Powell indicated in Congressional testimony earlier this month a 25 basis-point bump was distinctly possible.“By raising interest rates, the Federal Reserve has begun the process of unwinding their pandemic-era stimulus measures in an effort to tame inflation,” Bankrate chief financial analyst Greg McBride said in a note. “This isn’t a one-and-done but the start of a series of rate hikes for the remainder of this year and well into next.”The Fed also unveiled in its updated Summary of Economic Projections, or \"dot plot,\" which reflects the individual economic projections of policymakers on the Federal Open Market Committee, that the median member anticipates up to six more rate hikes in 2022, which would bring rates 1.75% higher at the end of this year. Before Wednesday’s decision, the benchmark interest rate was deliberately held near zero since mid-2020 as part of the Fed’s easy-money policies used to keep financial conditions running smoothly during the pandemic.“The Fed didn’t rock the boat much,” LPL Financial chief market strategist Ryan Detrick said. “Yes, they lowered economic expectations in 2022 while also increasing inflation, but much of that was already priced into things. Overall, they still see strong growth, which helps support the recovery.”Although the key decision provided some clarity to investors who for months have awaited for the central bank to take steps forward on tightening monetary conditions, the Fed’s path forward remains muddied by geopolitical turmoil in Eastern Europe. War in Ukraine and penalizing sanctions against Russia for its invasion of the country have raised uncertainty in recent weeks over the conflict’s toll on the global economic picture.The Fed acknowledged in a statement that came out of its meeting that implications for the U.S. economy are “highly uncertain” but likely to worsen already decades-high inflationary pressures.“Playing catch up is the theme that Fed officials signaled to markets today as the narrative has shifted from normalizing monetary policy to laying the groundwork for a more restrictive policy and moving beyond neutral,” Allianz Investment Management senior market strategist Charlie Ripley said in commentary.Elsewhere in markets, shares of Warren Buffett's Berkshire Hathaway closed at $500,000 for the first time on Wednesday. The price underscored Berkshire's status as a defensive stock at a time markets have been roiled by economic and geopolitical uncertainty.Berkshire's Class A shares have advanced 10% in 2022, even as the S&P 500 is down about 12% year-to-date. Prior to a relief rally on Wednesday, the benchmark index on Tuesday (the 50th trading day of the year) locked in its 6th worst start to a year ever, data from LPL financial reflected. The silver lining? The previous five worst starts were followed by notable gains, with an average gain for the rest of the year of 36%, with the exception of only 2001.“Although we aren’t expecting 36% gains the rest of this year, it does suggest that things might be quite bad now, but we’ve been here before and we’ve seen stocks come back way more than expected,” LPL’s Detrick said.","news_type":1,"symbols_score_info":{".SPX":0.9,".DJI":0.9,".IXIC":0.9}},"isVote":1,"tweetType":1,"viewCount":3082,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}